检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:肖骏[1] 李均[1] 岳瑞华[1] 沈钧乐[1] 张颖[1]
出 处:《重庆医学》2015年第22期3048-3049,3052,共3页Chongqing medicine
基 金:重庆市卫生计生委医学科研计划项目(20142083)
摘 要:目的探讨经自制带侧孔的快速交换球囊导管靶向注射替罗非班联合硝普钠对择期冠状动脉介入治疗(PCI)术中无复流(NR)的即刻疗效。方法选择2013年1月至2014年8月在该中心行择期PCI治疗中发生无复流的患者49例,随机分为经球囊导管给药组25例,经指引导管给药组24例。两组患者均给予替罗非班及硝普钠。评价给药前后冠状动脉血流心肌梗死溶栓试验(TIMI)分级及校正TIMI帧数(CTFC)。结果给药10min后,经球囊导管给药组有21例(84.0%)达到TIMI 3级血流,校正CTFC为(33.5±12.5)帧,而经指引导管给药组有13例(54.2%)达到TIMI 3级血流,CTFC为(41.9±15.3)帧,两组比较差异有统计学意义(P<0.05)。结论经自制带侧孔球囊导管靶向注射替罗非班联合硝普钠较经指引导管给药更能有效地改善择期PCI术中无复流患者冠状动脉的即刻血流。Objective To investigate the effects of tirofiban combined with nitroprusside injection through the rapid exchange balloon catheter with self-made side holes on no-reflow (NR) phenomenon during elective percutaneous coronary intervention (PCD. Methods A total of 49 patients with NR phenomenon were randomly divided into the balloon catheter group (n=25) and the guiding catheter group (n= 24). Tirofiban combined with nitroprusside were used in both groups. Thrombolysis in myocardial infarction (TIMI) grade and corrected TIMI frame count (CTFC) of target coronary artery at 10 minutes after administration were assessed. Results At 10 minutes after drugs injection,there were 21 (84.0%) patients with target of coronary TIMI 3 grade in the balloon catheter group, and 13 (54.2% ) patients in the guiding catheter group. The CTFC was (33.5± 12.5) frame in the balloon catheter group, and (41.9±15.3) frame in the guiding catheter group. The difference in TIMI and CTFC between the two groups was significantly (P〈0.05). Conclusion Injection tirofiban combined with nitroprusside through the rapid exchange balloon cathe- ter with self-made side holes in NR patients during elective PCI might be feasible and effective.
关 键 词:无复流现象 冠状血管 硝普钠 球囊导管 替罗非班
分 类 号:R541.4[医药卫生—心血管疾病]
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.28